Jamil Aboulhosn, MD
Cardiovascular Disease · Los Angeles, CANPI 1356382717
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Edwards Lifesciences at 51.7% of the total. Reporting peaked in 2022 at $122,517 and has fallen 70.8% since, to $35,819 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $845.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$219K
- Medtronic$138K
- Abbott$37K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16K
- Siemens Medical Solutions USA, Inc.$7K
- Actelion Pharmaceuticals US, Inc.$2K
- plus $4K from 10 others
Across 55 payments — averaging $4740.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$236K
- Abbott$17K
- Janssen Research & Development, LLC$8K
What the payments were for
- Consulting fees$216,40351%
- Speaking & faculty fees$155,26737%
- Travel & lodging$37,5159%
- Food & beverage$13,3283%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 222 | $218,533 |
| Medtronic(2 entities) | 205 | $137,612 |
| Abbott | 25 | $36,792 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $16,000 |
| Siemens Medical Solutions USA, Inc. | 6 | $6,849 |
| Actelion Pharmaceuticals US, Inc. | 9 | $2,325 |
| Actelion Pharmaceuticals, Ltd | 1 | $1,641 |
| Balt USA, LLC | 10 | $886 |
| Inceptus Medical, LLC | 1 | $645 |
| W. L. Gore & Associates, Inc. | 5 | $560 |
| Penumbra, Inc. | 2 | $380 |
| Galt Medical | 1 | $227 |
| B. Braun Interventional Systems Inc. | 1 | $85 |
| Astellas Pharma US Inc | 2 | $31 |
| Biotronik Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$134,304
- HARMONY$117,611
- THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$38,377
- AMPLATZER Occluders$21,591
- LifeVest$16,000
- Cardiovascular- Research only$11,520
- Melody$8,356
- ACUSON SC2000 Diagnostic Ultrasound System$6,460
- AMPLATZER PICCOLO$3,247
- OPSUMIT$2,020
- Prestige Coil System$666
- LOBO$645
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$557
- EVOQUE$432
- Product in Development$400
- Indigo System$235
- CoreValve Evolut$181
- Ruby$145
- AMPLATZER$132
- COREVALVE EVOLUT R$111
How this compares
$422,608 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $91,864 |
| FarxigaDapagliflozin Propanediol | 58 | $65,736 |
| Tadalafil | 17 | $18,639 |
| Repatha SureclickEvolocumab | 17 | $15,046 |
| Praluent PenAlirocumab | 22 | $10,649 |
| Potassium Chloride | 18 | $3,341 |
| Metoprolol Succinate | 70 | $1,394 |
| Spironolactone | 54 | $714 |
| Atorvastatin Calcium | 59 | $589 |
| Losartan Potassium | 54 | $490 |
| Furosemide | 81 | $489 |
| Digoxin | 20 | $428 |
| Metoprolol Tartrate | 30 | $287 |
| Carvedilol | 20 | $282 |
| Atenolol | 17 | $256 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.